Cancer Immunology, Immunotherapy

, Volume 62, Issue 12, pp 1821–1830

Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy

  • Saly Al-Taei
  • Russell Banner
  • Ned Powell
  • Mererid Evans
  • Nachi Palaniappan
  • Zsuzsanna Tabi
  • Stephen Man
Original Article

DOI: 10.1007/s00262-013-1488-5

Cite this article as:
Al-Taei, S., Banner, R., Powell, N. et al. Cancer Immunol Immunother (2013) 62: 1821. doi:10.1007/s00262-013-1488-5

Abstract

Oropharyngeal cancer (OPC) is a type of squamous cell head and neck cancer that is often associated with human papillomavirus (HPV) infection, suggesting the potential for immunotherapeutic targeting of HPV antigens. This study aimed to determine the effect of radical therapy on HPV-specific T cells and other immune parameters in 20 OPC patients, as a prelude to future immunotherapy studies. HPV DNA could be detected in 9/12 available tissue samples (8/9 HPV+ samples were also p16+). HPV-specific T cell responses against HPV16 E6 and E7 peptides were detected by enzyme-linked immunoSPOT in 10/13 and 8/13 evaluable patients, respectively, but did not appear to correlate with HPV status. Post-treatment, both HPV E6 and E7 T cell responses were decreased (4/13 and 2/13 patients, respectively). These reductions in T cell response could not be explained by a concurrent decrease in memory T cells whose absolute numbers were relatively unaffected by radical therapy (27,975 vs. 25,661/105 PBMC) despite a significant decrease in overall lymphocyte counts (1.74 vs. 0.69 × 109/L). Instead, there were significant increases in regulatory T cells (3.7 vs. 6.8 %) and a population of myeloid-derived suppressor cells (CD14HLA-DRCD15hi, 12.38 vs. 21.92 %). This suggests that immunosuppression may contribute to the reduction in HPV-specific T cell responses post-treatment, although study of larger patient cohorts will be required to test whether this affects clinical outcome. Overall these findings suggest that HPV-targeted immunotherapy in post-therapy OPC patients will require multiple strategies to boost T cell immunity and to overcome the influence of immunosuppressive cells.

Keywords

OPC HPV T cells Immunosuppression 

Supplementary material

262_2013_1488_MOESM1_ESM.pdf (1.1 mb)
Supplementary material 1 (PDF 1121 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Saly Al-Taei
    • 1
  • Russell Banner
    • 1
  • Ned Powell
    • 2
  • Mererid Evans
    • 1
  • Nachi Palaniappan
    • 1
  • Zsuzsanna Tabi
    • 1
  • Stephen Man
    • 2
  1. 1.Velindre Cancer CentreCardiffUK
  2. 2.Institute of Cancer and GeneticsCardiff University School of MedicineCardiffUK

Personalised recommendations